Figure 1. SP0969 trial design.

PBO = placebo. ^aThe highest possible dose per body weight category is shown for each taper period week. ^bPatients on lacosamide remained on their maintenance dose during the transition period, whereas patients in the placebo group initiated lacosamide in a double-blind fashion. On completion of the transition period, eligible patients entered the open-label extension on a weight-based dose (<30 kg: 10 mg/kg/d; ≥30–<50 kg: 6 mg/kg/d; ≥50 kg: 300 mg/d).